293 related articles for article (PubMed ID: 17375031)
1. Pramipexole (Mirapex) for restless legs syndrome.
Med Lett Drugs Ther; 2007 Mar; 49(1257):26-8. PubMed ID: 17375031
[No Abstract] [Full Text] [Related]
2. Pramipexole: new indication. Restless legs: still no satisfactory drug treatment.
Prescrire Int; 2007 Feb; 16(87):12. PubMed ID: 17323517
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with pramipexole in the treatment of restless legs syndrome.
Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.
Inoue Y; Hirata K; Kuroda K; Fujita M; Shimizu T; Emura N; Uchimura N; Kagimura T; Sha K; Nozawa T
Sleep Med; 2010 Jan; 11(1):11-6. PubMed ID: 19962941
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2006 Aug; 7(5):407-17. PubMed ID: 16815748
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.
Montagna P; Hornyak M; Ulfberg J; Hong SB; Koester J; Crespi G; Albrecht S
Sleep Med; 2011 Jan; 12(1):34-40. PubMed ID: 20965780
[TBL] [Abstract][Full Text] [Related]
7. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials.
Hornyak M; Sohr M; Busse M;
Sleep Med; 2011 Feb; 12(2):186-9. PubMed ID: 21256799
[TBL] [Abstract][Full Text] [Related]
9. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
[TBL] [Abstract][Full Text] [Related]
10. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pramipexole in chinese patients with restless legs syndrome: results from a multi-center, randomized, double-blind, placebo-controlled trial.
Ma JF; Wan Q; Hu XY; Sun SG; Wang WZ; Zhao ZX; Wang YJ; Liu CF; Li JM; Jiang YP; Chen SD
Sleep Med; 2012 Jan; 13(1):58-63. PubMed ID: 22137119
[TBL] [Abstract][Full Text] [Related]
12. Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS.
Varga LI; Ako-Agugua N; Colasante J; Hertweck L; Houser T; Smith J; Watty AA; Nagar S; Raffa RB
J Clin Pharm Ther; 2009 Oct; 34(5):493-505. PubMed ID: 19744006
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of cluster headache with pramipexole.
Ossemann M
Acta Neurol Belg; 2010 Sep; 110(3):279-80. PubMed ID: 21114140
[TBL] [Abstract][Full Text] [Related]
15. Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep.
Manconi M; Ferri R; Zucconi M; Clemens S; Rundo F; Oldani A; Ferini-Strambi L
Sleep Med; 2011 Jan; 12(1):47-55. PubMed ID: 20851046
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic treatment in idiopathic restless legs syndrome: effects on subjective sleepiness.
Kallweit U; Khatami R; Pizza F; Mathis J; Bassetti CL
Clin Neuropharmacol; 2010; 33(6):276-8. PubMed ID: 21060282
[TBL] [Abstract][Full Text] [Related]
17. Pramipexole: in restless legs syndrome.
McCormack PL; Siddiqui MA
CNS Drugs; 2007; 21(5):429-37; discussion 438-40. PubMed ID: 17447832
[TBL] [Abstract][Full Text] [Related]
18. [Impulse control disorder induced by the use of dopamine agonists].
Weber WE; Nijssen PC
Ned Tijdschr Geneeskd; 2009 Jan; 153(3):80-1. PubMed ID: 19235343
[No Abstract] [Full Text] [Related]
19. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome.
Högl B; Garcia-Borreguero D; Trenkwalder C; Ferini-Strambi L; Hening W; Poewe W; Brenner SS; Fraessdorf M; Busse M; Albrecht S; Allen RP
Sleep Med; 2011 Apr; 12(4):351-60. PubMed ID: 21354368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
